Medicines for overweight
The fight against overweight and obesity is undergoing a major revolution with new medicines promising significant, lasting weight loss. Three names regularly feature in medical news and the media: Ozempic, Wegovy and Mounjaro. Initially developed for type 2 diabetes, these treatments quickly attracted worldwide enthusiasm because of their effectiveness for weight loss.
Faced with growing public interest, the Food and Drug Administration, the US medicines regulator, has intensified its analysis to assess these molecules' effectiveness and risks precisely. Accumulating scientific data now provide a better understanding of both the potential and limitations of these new therapies.
Cryolipolysis in Geneva: an effective alternative to Ozempic for localised slimming
Although medical treatments such as Ozempic, Wegovy or Mounjaro allow overall weight loss, they do not target persistent localised fat deposits. Cryolipolysis, offered by Dr Romano in Geneva, is an ideal solution for precisely refining and sculpting the figure. This non-invasive technique uses controlled cooling of fat cells, causing their natural destruction without surgery or social downtime. A few sessions can treat stubborn localised fat deposits such as the abdomen, love handles, thighs or double chin. Results are gradual and harmonious.
Sculptra for buttocks in Geneva: treating cellulite and naturally restoring shape
Buttock cellulite may persist despite weight loss achieved with treatments such as Ozempic or Mounjaro. Sculptra, a polylactic acid biostimulator, firms the skin, stimulates collagen production and improves skin quality. Used on the buttocks, it helps smooth the skin, correct dimpling and restore natural shape without surgery. This treatment is particularly appreciated in Geneva for its gradual, lasting results. The skin is visibly firmer.
Proven but conditional effectiveness
Results observed with these treatments are spectacular, particularly compared with previous pharmacological approaches. However, their effectiveness depends on several conditions.
First, treatment must be regular and prolonged. Stopping often leads to weight regain, raising the question of long-term dependence. Secondly, these medicines do not replace the fundamentals of a healthy lifestyle. Without dietary adjustments and physical activity, benefits remain limited.
The FDA also stresses the need for careful patient selection. These medicines are intended for medical treatment of overweight and obesity, chronic conditions with serious health consequences, rather than occasional aesthetic weight loss.
Ozempic: a diabetes medicine turned slimming star
Ozempic contains semaglutide, a molecule belonging to the GLP-1 receptor agonist class. Its original role is to improve blood glucose regulation in people with type 2 diabetes. By acting on intestinal receptors, semaglutide stimulates insulin secretion and reduces appetite.
Doctors soon observed significant weight loss in their diabetic patients. This side effect proved so interesting that it opened the way to new indications. Today, Ozempic is frequently prescribed for weight loss, unfortunately sometimes outside official recommendations.
Wegovy: the version officially approved for obesity
Wegovy is actually a higher-dose semaglutide formulation. Unlike Ozempic, it received specific FDA approval for treating overweight and obesity. Clinical trials showed that patients could lose up to fifteen per cent of their body weight, a major advance over previous treatments.
Wegovy is therefore presented as a validated medical solution supporting patients towards lasting weight loss. However, its effectiveness depends on regular, prolonged use combined with an appropriate lifestyle.
Mounjaro: the new generation of agonists
Mounjaro, whose active molecule is tirzepatide, belongs to an even newer generation. It acts on both GLP-1 and GIP receptors, two intestinal hormones involved in blood glucose and appetite regulation. This dual action gives Mounjaro greater potency, with weight loss results exceeding those observed with semaglutide.
Clinical studies show weight loss of up to twenty per cent of initial weight, placing tirzepatide at the forefront of therapeutic hopes in fighting obesity. The FDA is closely monitoring this medicine because of its impressive effectiveness and safety questions that remain to be clarified.
Risks and side effects
The other major aspect under FDA scrutiny concerns risks. Like all medicines, these treatments have side effects. The most frequent affect the digestive system: nausea, vomiting, diarrhoea or constipation. These symptoms may be temporary but are sometimes troublesome enough to lead to discontinuation.
Questions also persist about more serious risks. Some signals suggest a possible increased risk of pancreatitis or even thyroid conditions. Although these links are not formally established, caution remains necessary. The FDA is requesting additional long-term studies to assess these molecules' safety fully.
Enthusiasm extending beyond medicine
The success of Ozempic, Wegovy and Mounjaro is not explained solely by clinical results. Social media, influencers and some celebrities have made them desirable, presenting them as quick weight loss solutions. This publicity creates two risks.
The first is trivialisation: many people seek these treatments without a medical indication, sometimes through unsafe channels. The second is shortages: massive demand strains production, sometimes depriving diabetic patients for whom these medicines are vital.
